Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy.
Wee Y, Wang J, Wilson EC, Rich CP, Rogers A, Tong Z, DeGroot E, Gopal YNV, Davies MA, Ekiz HA, Tay JKH, Stubben C, Boucher KM, Oviedo JM, Fairfax KC, Williams MA, Holmen SL, Wolff RK, Grossmann AH. Wee Y, et al. Among authors: grossmann ah. Nat Commun. 2024 Aug 4;15(1):6613. doi: 10.1038/s41467-024-50881-1. Nat Commun. 2024. PMID: 39098861 Free PMC article.
Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment.
Smith EA, Belote RL, Cruz NM, Moustafa TE, Becker CA, Jiang A, Alizada S, Chan TY, Seasor TA, Balatico M, Cortes-Sanchez E, Lum DH, Hyngstrom JR, Zeng H, Deacon DC, Grossmann AH, White RM, Zangle TA, Judson-Torres RL. Smith EA, et al. Among authors: grossmann ah. bioRxiv [Preprint]. 2024 Jun 17:2024.06.15.599116. doi: 10.1101/2024.06.15.599116. bioRxiv. 2024. PMID: 38948879 Free PMC article. Preprint.
ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancer.
Wee Y, Wang J, Wilson EC, Rich CP, Rogers A, Tong Z, DeGroot E, Gopal YNV, Davies MA, Ekiz HA, Tay JKH, Stubben C, Boucher KM, Oviedo JM, Fairfax KC, Williams MA, Holmen SL, Wolff RK, Grossmann AH. Wee Y, et al. Among authors: grossmann ah. bioRxiv [Preprint]. 2023 Oct 2:2023.09.29.560199. doi: 10.1101/2023.09.29.560199. bioRxiv. 2023. Update in: Nat Commun. 2024 Aug 4;15(1):6613. doi: 10.1038/s41467-024-50881-1 PMID: 37873189 Free PMC article. Updated. Preprint.
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
Battin C, De Sousa Linhares A, Leitner J, Grossmann A, Lupinek D, Izadi S, Castilho A, Waidhofer-Söllner P, Grabmeier-Pfistershammer K, Stritzker J, Steinberger P. Battin C, et al. Among authors: grossmann a. Cancer Immunol Immunother. 2023 Sep;72(9):3029-3043. doi: 10.1007/s00262-023-03474-8. Epub 2023 Jun 13. Cancer Immunol Immunother. 2023. PMID: 37310433 Free PMC article.
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
Brunsgaard EK, Bowles TL, Asare EA, Grossmann K, Boucher KM, Grossmann A, Jackson JA, Wada DA, Rathore R, Budde G, Grandemange A, Hyngstrom JR. Brunsgaard EK, et al. Among authors: grossmann a. Melanoma Res. 2023 Jun 1;33(3):184-191. doi: 10.1097/CMR.0000000000000892. Epub 2023 Apr 5. Melanoma Res. 2023. PMID: 37040662 Free PMC article.
[Fatal neurological side effect of anti-CD20 antibody treatment].
Schmidt K, Skusa R, Großmann A. Schmidt K, et al. Among authors: grossmann a. Inn Med (Heidelb). 2023 Feb;64(2):193-196. doi: 10.1007/s00108-022-01431-8. Epub 2022 Nov 23. Inn Med (Heidelb). 2023. PMID: 36422661 Free PMC article. German.
223 results